CN105294724A - Clerodane-type diterpene compound and preparation method and medical application thereof - Google Patents
Clerodane-type diterpene compound and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105294724A CN105294724A CN201510676623.5A CN201510676623A CN105294724A CN 105294724 A CN105294724 A CN 105294724A CN 201510676623 A CN201510676623 A CN 201510676623A CN 105294724 A CN105294724 A CN 105294724A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- extract
- compound according
- elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a clerodane-type diterpene compound and a preparation method and medical application thereof. The compound is first reported, is a diterpene compound of a novel structure and can be obtained through performing extraction, separation and purification on dry and mature seeds of hance. An in vitro test verifies that the compound has an effect on resisting human neurospongioma cells U251 and can be used for developing medicine for treating human neurospongioma.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry mature seed of Semen Caesalpiniae Minacis, be separated obtain a kind of and there is Crow alkane type diterpene-kind compound for the treatment of human glioma effect and preparation method thereof.
Background technology
Semen Caesalpiniae Minacis (Hance) is the seed of leguminous plants south snake Jin, has another name called beak pod mysorethorn, crow pillow.Its property bitter cold, the thoughts of returning home, spleen, kidney channel, be a kind of medicinal and edible plant, be mainly distributed in the ground such as Guangdong, Guangxi, Sichuan, Yunnan.Have clearing away heat and eliminating dampness, the effects such as blood stasis removing analgesic, be usually used in common cold due to wind-heat, dysentery stranguria with turbid discharge, hiccup, carbuncle swells, sore tinea, the diseases such as wound.
Semen Caesalpiniae Minacis is mainly containing number of chemical compositions such as diterpenes, flavonoid, unsaturated fatty acidss.The most active to the research of diterpenes in Semen Caesalpiniae Minacis chemical constitution study, study and found that new, a large amount of diterpene-kind compound majority has stronger pharmacologically active.
Semen Caesalpiniae Minacis has the basis of medication widely as a kind of medicine resource in influenza, hepatitis B, the tetter etc. of being used for the treatment of among the people always, and it has the pharmacological actions such as anti-inflammatory, analgesia, antiviral, antitumor, anti-liver injury, reducing blood-fat, atherosclerosis.The research such as Wang Han finds that the different extraction components of Semen Caesalpiniae Minacis can effectively suppress interleukin-6 in THP-1 cell, the secretion of interleukin-8, thus plays anti-inflammatory, analgesic activity.The Semen Caesalpiniae Minacis protein of separation and purification from Semen Caesalpiniae Minacis such as Wu Zhaohua has the activity and bacteriostatic activity that suppress mouse melanin tumor cell propagation; From its seed, be separated beak pod mysorethorn star (minaxinA) obtained find that it has restraining effect to the growth of human hepatoma HepG2 cell after deliberation.The Semen Caesalpiniae Minacis ethanol extraction preventive administration such as Liu Ming; be research object with liver injury model caused by tetracol phenixin; result of study shows: Semen Caesalpiniae Minacis ethanol extraction can suppress acute liver serum AST and ALT level, has provide protection to acute liver.The linolic acid contained in Semen Caesalpiniae Minacis, oleic acid, etc. unsaturated fatty acids have and reduce blood fat and cholesterol, minimizing atherosclerosis, anticancer growth and promote the effects such as brain development.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry mature seed of Semen Caesalpiniae Minacis, be separated obtain a kind of there is Crow alkane type diterpene-kind compound for the treatment of human glioma effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry mature seed of (a) Semen Caesalpiniae Minacis is pulverized, extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract; C in () step (b), 70% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 75% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
A kind of pharmaceutical composition, this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment human glioma.
The application of described pharmaceutical composition in the medicine of preparation treatment human glioma.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry mature seed (8kg) of Semen Caesalpiniae Minacis is pulverized by (a), (25L × 3 time) are extracted with 75% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (347g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, use 70% ethanol elution, 12 column volumes again, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract (129g); C in () step (b), 70% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 30:1 (6 column volumes), 10:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 15:1 (8 column volumes), the methylene chloride-methanol gradient elution of 10:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (14g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (48mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z395.1102, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
20h
20o
7, degree of unsaturation is 11.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 500MHz): H-2 (5.86, d, J=10.0), H-3 (5.47, dd, J=10.0, 2.5), H-4 (2.66, d, J=2.5), H-6 (1.69, dd, J=14.5, 4.0), H-6 (1.27, dddd, J=14.5, 14.5, 4.0, 2.0), H-7 (1.76, ddd, J=17.5, 6.5, 4.0), H-7 (2.39, m), H-11 (2.35, m), H-11 (2.55, dd, J=14.0, 3.5), H-12 (5.72, dd, J=12.5, 3.5), H-14 (6.39, dd, J=2.0, 1.0), H-15 (7.30, t, J=2.0), H-16 (7.36, t, J=1.0), H-19 (4.19, d, J=9.0), H-19 (4.08, dd, J=9.0, 2.0), H-20 (1.01, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125MHz): 200.8 (C, 1-C), 134.5 (CH, 2-C), 118.2 (CH, 3-C), 51.1 (CH, 4-C), 41.0 (C, 5-C), 31.6 (CH
2, 6-C), 25.9 (CH
2, 7-C), 74.3 (C, 8-C), 39.2 (C, 9-C), 43.0 (CH, 10-C), 34.8 (CH
2, 11-C), 71.3 (CH, 12-C), 124.7 (C, 13-C), 107.8 (CH, 14-C), 142.1 (CH, 15-C), 138.4 (CH, 16-C), 171.5 (C, 17-C), 174.1 (C, 18-C), 69.5 (CH
2, 19-C), 17.1 (CH
3, 20-C), carbon atom mark is see Fig. 1.IR spectrum shows that this compound contains hydroxyl (3472cm
-1), lactone (1762 and 1734cm
-1) and furan nucleus (879cm
-1) group.
13cNMR spectrum shows 20 signals, containing a methyl, four methylene radical (comprising containing Oxymethylene), eight methynes (comprise five alkene carbon and one containing oxygen carbon) and eight quaternary carbons (comprise three carbonyl carbon, an alkene carbon and one contain oxygen quaternary carbon).According to
1h and
13cNMR modal data is analyzed this compound known and is contained 12,17-delta-lactones (δ H5.72, δ C71.3, CH-12; δ C171.5, C-17) and 18,19-gamma lactone (δ C174.1, C-18; δ H4.19,4.08, δ C69.5, CH
2-19).In addition, quaternary carbon is in the chemical shift (δ C74.3) of low field, shows that C-8 position exists a hydroxyl.According to H-12 (δ H5.72 in HMBC spectrum, dd, J=12.5,3.5) and C-13 (δ C124.7), the dependency of C-14 (δ C107.8) and C-16 (δ C138.4), deducibility furan nucleus is positioned on C-12 (δ C71.3) position.H in HMBC spectrum
2-6, H
2-7, H-10, H
2-11 and H
3-20 with the relevance verification of C-8 above-mentioned inference, and be α configuration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
Human glioma cell's strain U251 is purchased from Mai Sha bio tech ltd, Shanghai.Laboratory animal nude mice, purchased from Nanfang Medical Univ's Experimental Animal Center, is male BALB/c, the nu/nu mouse in 4 ~ 6 week age, weight 12 ~ 15g.Compound (I) self-control (content more than 98%).5 FU 5 fluorouracil is purchased from Nantong pharmaceutical factory, trypsinase is purchased from Amresco company of the U.S., incomplete DMEM substratum is purchased from GibeoBRL company, foetal calf serum is purchased from Hangzhou folium ilicis chinensis company, sodium lauryl sulphate, ethylenediamine tetraacetic acid (EDTA), Ammonium Persulfate 98.5, glycerine, dimethyl alum is purchased from Sigma company, Proteinase K (Merka company), P-coloured glaze base ethanol (Guangzhou Wei Jia company), phenmethyl sulfonephthalein fluorine (Guangzhou Wei Jia company), bright press down enzyme skin (Guangzhou Wei Jia company), press down proteolytic enzyme skin (Guangzhou Wei Jia company), propylene phthalein amine (Shanghai Sheng Gong bio-engineering corporation), two propylene phthalein amine (Shanghai Sheng Gong bio-engineering corporation).
Opticmicroscope (OLYMPUSBxsl, Japan), Olympus digital camera (OlympusD70, Japan), photomicrography system (CoolSNAP-Proofmonoehrome, the U.S.), PL303 type electronic balance (plum Teller-Tuo benefit Instrument Ltd.), 6219 type electronics pH meters (Shanghai Ren Shi Electronics Co., Ltd.), 3K30 high speed low temperature centrifugal machine (sigma company), HoferMiniVE type westem electrophoresis marking system (Amersham company of the U.S.), SYC-2101 horizontal shaker (Nanjing Chang Xiang plant and instrument limited liability company), high speed tabletop centrifuge (Heima Medical Instrument Co., Ltd., Zhuhai City), miniature electrophoresis and electrotransfer system (BIO-RAD company of the U.S.), three gas cell culture incubator 1750 types (French Jouan company), MODEL5410 water purifior Milli-Qplus type (French Millipore company), water isolation type electro-heating standing-temperature cultivator (Shanghai leap medical apparatus and instruments factory), SHW-1 type constant temperature blender with magnetic force (Hangzhou motor for instrument factory), YG-875B Bechtop (Suzhou Medical Equipment Plant), continuous wavelength microplate reader (BenchnlarkPlusTM, Bio-RAD company), inverted microscope (Japanese Nicon company), Full automatic sterilizing pot (Japanese sanyo company), desk-top low-temperature and high-speed whizzer (Bechman company), electrophoresis apparatus (PowerPAL3000, Bio-RAD company), DU640 type ultraviolet spectrophotometer (Beeklllan company of the U.S.).
Two, test method
1, cell cultures
Human glioma U251 cell uses DMEM substratum (containing 10%FBS) to cultivate after recovering in conventional manner.Cell is cultivated with the culture dish of 60mm, adds 3mLDMEM perfect medium.When cell grows to 80% fusion, rinse twice with HankS balanced salt solution (HBSS), change before being cultured to drug treating with the DMEM not containing serum.
2, the process of compound (I)
Compound (I) is dispersed in the incomplete substratum of DMEM after first dissolving with DMSO0.1mL.Compound (I) concentration of final process cell is 100,500,1500 μm of ol/L, continues to give anoxic and cultivate after process lh.
3, compound (I) vitro inhibition cell proliferation experiment
Bibliographical information compound (I), in 50 μm of ol/L concentration ranges, to SMMC7721 cell both without significant growth-inhibiting, does not significantly increase the apoptosis rate in flow cytomery yet.This research selects the compound (I) of 0-200 μm of ol/L concentration to test.Different concns compound (I) 100 μ L is added respectively in 96 orifice plates, medicine final concentration is made to be 5 μm of ol/L, 10 μm of ol/L, 25 μm of ol/L, 50 μm of ol/L, 100 μm of ol/L, 200 μm of ol/L, every concentration establishes 6 multiple holes, positive drug control group adds 5 FU 5 fluorouracil (5-Fluorouracil, 5-FU) 10 μ g/mL, control wells adds equal-volume DMEM nutrient solution.Get the complete DMEM substratum of cell exponential phase of growth after cell strain cellar culture and be adjusted to (l ~ 2) × 10
5individual/mL, every hole inoculating cell suspension 100 μ L.After cultivating 48h, degree of cell proliferation is detected with mtt assay, every hole adds 2.5mg/mLMTT20 μ L, continue to cultivate 4h, centrifugally carefully discard nutrient solution afterwards, every hole adds 150 μ LDMSO, earthquake device to shake after 10min in microplate reader with 570nm wavelength detecting, measure the optical density value (OD) in each hole, inhibiting rate is by following formulae discovery: inhibiting rate (%)=(1-medicine feeding hole mean OD value/control wells mean OD value) × 100%.
4, nude mouse U251 transplanted sarcoma growth experiment is suppressed in compound (I) body
After the U251 cell expansion cultivation of vitro culture, the cell culture system of growth selection optimum regime, centrifugal, with physiological saline 1:3 (tumour cell: physiological saline) dilution by volume mixing.Above-mentioned cell suspension 0.15mL is drawn with lmL disposable syringe, inguinal region is inoculated in subcutaneous through mouse right hind leg muscle, then blank group of (Untreated is divided at random, isometric(al) NS), solvent control group (vehide, isometric(al) NS+DMSO), compound (I) 1.0,2.0mmol/kg abdominal injection group, often organize 6, by the administration of 0.1mL/10g body weight, ring phosphorus phthalein amine (Cyelophosphamide, CTX) positive controls is 0.02g/kg body weight intraperitoneal injection.Once a day, after successive administration 10d, put to death mouse, be separated tumour and weigh.Tumour inhibiting rate (%)=(the average knurl weight of l-administration group average knurl weight/control group) × 100%.
5, statistical study
Adopt SPSS13.0 statistical analysis software, data with
represent, carry out statistical test through one-wayANOVA (multiple comparisons LSD method), independentsamplest-test, specifically see each data form and chart, being decided to be difference with P≤0.05 has statistical significance.
Three, result and conclusion
1, the single medicine process of compound (I) is on the impact of U251 cell proliferation
Absorbance (optiealdensity, the OD of each hole under 570nm is detected by MTT detection method
570), the activity of U251 cell proliferation is reflected with this.Each group of OD
570value is through homogeneity test of variance, and P=0.460, illustrates homoscedasticity; Through One-way ANOVA, F=57.577, P=0.121, illustrate that group difference does not have statistical significance.Prompting compound (I) is external does not have restraining effect to the propagation of U251 cell under≤200 μm of ol/L administration concentration.The results are shown in Table 1 (one-wayANOVA:P=0.121 >=0.05).
2, the single medicine process of compound (I) is to the tumor-inhibiting action of tumor-bearing mice
Each group of knurl weight values is through homogeneity test of variance, and F=l.903, P=0.141, illustrate homoscedasticity; Through One-way ANOVA, F=17.931, P=0.000, illustrate that group difference has statistical significance, needs to adopt LSD method of inspection row multiple comparisons further.Compound (I) dosage is 1.0, the treatment group of 2.0mmol/kg abdominal injection group compares with solvent control group (Vehiele), P value is respectively: 0.000,0.000, illustrate that difference has statistical significance, prompting is by intraperitoneal injection, and compound (I) is to lotus U251 effect, and tumor-inhibiting action has to be increased with dosage and strengthen trend.In table 2 (LSDtest:*P≤0.05vsVehiclegroup).
Conclusion, the experimental result of the single medicine process of compound (I) to U251 cel l proliferation shows, the external propagation to U251 cell of compound (I) does not have restraining effect, illustrate that compound (I) process in range of doses does not significantly affect the growth of tumour cell, prompting compound (I) does not have direct cell toxicant or cell death inducing effect to U251 cell.And in the tumor-inhibiting action experiment of compound (I) to lotus U251 solid tumor nude mouse, find that compound (I) dosage is 1.0, during 2.0mmol/kg, certain tumor-inhibiting action is shown to lotus U251 solid tumor nude mouse, and tumor-inhibiting action increases with dosage and strengthens.In conjunction with above-mentioned experimental result, illustrate that compound (I) has certain anti-U251 function of tumor, its effect be by cell toxicant or apoptosis-induced beyond certain mechanism realize.
Table 1 compound (I) to the effect of U251 human glioma cell in-vitro multiplication (n=6,
)
Table 2 compound (I) intraperitoneal injection to the tumor-inhibiting action of lotus U251 solid tumor nude mouse (n=6,
)
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry mature seed of Semen Caesalpiniae Minacis is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% ethanol eluate, concentrating under reduced pressure obtains 70% ethanol elution thing medicinal extract; C in () step (b), 70% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 75% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment human glioma.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment human glioma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510676623.5A CN105294724A (en) | 2015-10-16 | 2015-10-16 | Clerodane-type diterpene compound and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510676623.5A CN105294724A (en) | 2015-10-16 | 2015-10-16 | Clerodane-type diterpene compound and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105294724A true CN105294724A (en) | 2016-02-03 |
Family
ID=55192629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510676623.5A Pending CN105294724A (en) | 2015-10-16 | 2015-10-16 | Clerodane-type diterpene compound and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105294724A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175428A (en) * | 2015-10-26 | 2015-12-23 | 章丽珍 | New clerodane diterpenoid compounds, and preparation method and medical application thereof |
| CN105294727A (en) * | 2015-10-09 | 2016-02-03 | 杭州启澄科技有限公司 | Novel clerodane diterpenoid compound, preparation method of clerodane diterpenoid compound and medical application of novel clerodane diterpenoid compound |
| US9644152B2 (en) | 2013-09-18 | 2017-05-09 | Shell Oil Company | Methods and systems for supplying hydrogen to a hydrocatalytic reaction |
-
2015
- 2015-10-16 CN CN201510676623.5A patent/CN105294724A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| ELIHU BAUTISTA, ET AL.,: "neo-Clerodane Diterpenes from Salvia herbacea", 《J. NAT. PROD.》 * |
| ELIHU BAUTISTA,ET AL.,: "Hydroxyclerodanes from Salvia shannoni", 《J. NAT. PROD.》 * |
| MATIAS NIETO,ET AL.,: "8-Hydroxysalviarin and 7,8-Didehydrorhyacophiline, Two New Diterpenes from Salvia reflexa", 《J. NAT. PROD.》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9644152B2 (en) | 2013-09-18 | 2017-05-09 | Shell Oil Company | Methods and systems for supplying hydrogen to a hydrocatalytic reaction |
| CN105294727A (en) * | 2015-10-09 | 2016-02-03 | 杭州启澄科技有限公司 | Novel clerodane diterpenoid compound, preparation method of clerodane diterpenoid compound and medical application of novel clerodane diterpenoid compound |
| CN105175428A (en) * | 2015-10-26 | 2015-12-23 | 章丽珍 | New clerodane diterpenoid compounds, and preparation method and medical application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105085539A (en) | Novel diterpenoid compound, preparation method thereof and medical application | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105111269A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN106176716B (en) | The new application of daphane diterpene compound pimelotide C | |
| CN105218489A (en) | A kind of assorted terpene compound newly and preparation method thereof and medicinal use | |
| CN105198893A (en) | Diterpenoid compounds for treating stomach cancer | |
| CN105175481A (en) | Highly-oxidized diterpenoid compound and preparation method and medical application thereof | |
| CN105330673A (en) | Novel limonin compound and preparation method and medical application thereof | |
| CN105294724A (en) | Clerodane-type diterpene compound and preparation method and medical application thereof | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105330714A (en) | Novel limonin compound as well as preparation method and medical application thereof in treatment of prostatic cancer | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105503778A (en) | Grayanotoxin compound and preparation method and medical application thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105153263A (en) | New limonin compound as well as preparation method and medical application thereof | |
| CN105669605A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105503896A (en) | New phloroglucin compounds, and preparation method and medical application thereof | |
| CN105001230A (en) | Sesquiterpene compound, pharmaceutical composition containing sesquiterpene compound, and preparation method and applications of sesquiterpene compound | |
| CN105534968A (en) | Application of diterpenoid compound to preparation of drug for treating prostate cancer | |
| CN105461732A (en) | Novel diterpenoid compound and preparation method and medical application thereof | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105622629A (en) | Kaurane type diterpenoid compound for treating prostatic cancer | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |